Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

LILLY-PORTUGAL PRODUTOS FARMACÊUTICOS LDA

NIF 500165602
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €5,973,771 39 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €5,973,771 39 contracts
A2 · Late Publication €163,120,899,724 1,974 contracts
Contract published to BASE more than 10 days after the signing date
LOW €163,120,899,724 1,974 contracts
A5 · Threshold Splitting €9,174,335 74 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €9,174,335 74 contracts
A6 · Low Competition €2,517,511 29 contracts
Only one bidder participated in a competitive procedure
MEDIUM €2,517,511 29 contracts
A9 · Price Overrun €87,496 3 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €48,172 1 contracts
MEDIUM €39,324 2 contracts
A9 · Abnormal Price Reduction €166,650,922,544 973 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €166,650,922,544 973 contracts
B5 · Benford's Law Deviation €147,456,136,800 1 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €147,456,136,800 1 contracts
C3 · Missing Mandatory Fields €2,344,688 41 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €2,344,688 41 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

48
€148,111,495,210
320
€3,143,255,591
37
€640,580,803
174
€616,647,934
131
€610,415,497
49
€598,113,865
21
€596,211,790
90
€596,055,636
118
€576,152,448
28
€568,112,332
48
€557,656,688
274
€555,949,159
9
€555,906,932
29
€545,268,445
19
€538,158,250
8
€535,170,486
39
€520,053,551
14
€511,618,075
16
€507,406,114
27
€494,885,385
Page 1 of 4 · 62 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C3 · Missing Mandatory Fields

Page 1 of 1 · 29 contracts

EAD20250074 - AQUISIÇÃO DE MEDIC. USADOS TRAT.HIPERTENSÃO PULMONAR - TADALAFIL
PT · 11276418 · Ajuste Direto Regime G...
A6 · Low Competition
€10,843 2025-03-11
Aquisição de medicamentos do foro oncológico e imunomodulares II
PT · 11260543 · Ao abrigo de acordo-qu...
A6 · Low Competition
€39,914 2025-02-28
PIRTOBRUTINIB 100 MG COMP
PT · 11289123 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€234,532 2025-02-13
4525700081 | LM 006/2025 | Aquisição de Medicamentos de uso humano
PT · 11224566 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A6 · Low Competition
€69,521 2025-02-13
251G000239 - RAMUCIRUMAB 100MG/ 10ML INJ FR 10ML
PT · 11194613 · Ajuste Direto Regime G...
A6 · Low Competition
€8,315 2025-01-29
Aquisição de Medicamentos Exclusivos LILLY PORTUGAL para o ano de 2025
PT · 11243295 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€106,100 2025-01-21
INIBIDORES DE TIROSINACINASES - ABEMACICLIB
PT · 11101229 · Ao abrigo de acordo-qu...
A6 · Low Competition
€67,716 2024-12-20
EX/3494/2024 - SELPERCATINIB 80MG CP
PT · 11123364 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€45,971 2024-12-19
PIRTOBRUTINIB 100 MG COMP
PT · 11096650 · Ajuste Direto Regime G...
A6 · Low Competition
€20,940 2024-12-12
PIRTOBRUTINIB 100 MG COMP
PT · 11096607 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€20,940 2024-12-02
AQUISIÇÃO DE INSULINA LISPRO 100 U.I./ML ACÇÃO CURTA SOL INJ CARTU 3 ML IV SC
PT · 11032496 · Ao abrigo de acordo-qu...
A6 · Low Competition
€252 2024-11-18
INIBIDORES DE TIROSINACINASES - ABEMACICLIB
PT · 11007176 · Ao abrigo de acordo-qu...
A6 · Low Competition
€33,858 2024-11-04
INIBIDORES DE TIROSINACINASES - ABEMACICLIB - 3 MESES
PT · 10931853 · Ao abrigo de acordo-qu...
A6 · Low Competition
€22,572 2024-09-23
Fornecimento de substância ativa: Ramucirumab 500mg
PT · 10852456 · Ao abrigo de acordo-qu...
A6 · Low Competition
€135,127 2024-08-02
EX/2463/2024 - SELPERCATINIB 80MG CP Medicamento A.U.E
PT · 10894450 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€372,977 2024-07-31
EX/2445/2024 - PIRTOBRUTINIB 100MG COMP Medicamento A.U.E
PT · 10894430 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€218,400 2024-07-31
BEAD20240390 - AQUISIÇÃO DE INIBIDORES DE TIROSINACINASES - ABEMACICLIB - 3 MESES
PT · 10831867 · Ao abrigo de acordo-qu...
A6 · Low Competition
€22,572 2024-07-22
IMUNOMODULADORES - BARICITINIB
PT · 10723607 · Ao abrigo de acordo-qu...
A6 · Low Competition
€9,240 2024-05-17
Aquisição de: Medicamento Exclusivo LILLY PORTUGAL – PRODUTOS FARMACEUTICOS, LDA (SELPERCATINIB 80 MG CÁPS)
PT · 10762011 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€43,369 2024-05-09
SELPERCATINIB 80 MG CÁPS
PT · 10983420 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€225,393 2024-04-15
Aquisição de Medicamentos de uso humano
PT · 10667760 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A6 · Low Competition
€15,146 2024-04-15
Aquisição de TADALAFIL 20 MG COMP
PT · 10939487 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€52,600 2024-03-25
EAD20240052 - AQUISIÇÃO DE SELPERCATINIB
PT · 10589054 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction A6 · Low Competition
€112,760 2024-02-27
MEDICAMENTOS USADOS TRATAMENTO HIPERTENSÃO PULMONAR
PT · 10578085 · Ajuste Direto Regime G...
A6 · Low Competition
€14,597 2024-02-23
Fornecimento de Ramucirumab ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 10613714 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€43,656 2024-02-22
INIBIDORES DE TIROSINACINASES - 1º SEMESTRE
PT · 10570455 · Ao abrigo de acordo-qu...
A6 · Low Competition
€37,620 2024-02-20
Aquisição de “RAMUCIRumab 10 mg/ml Sol inj Fr IV”
PT · 10580004 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€55,436 2024-02-08
BEAD20240050 - AQUISIÇÃO DE IMUNOMODULADORES - BARICITINIB E IXECIZUMAB - 1º SEMESTRE
PT · 10520235 · Ao abrigo de acordo-qu...
A6 · Low Competition
€58,629 2024-01-26
Aquisição Medicamentos por AUE
PT · 10882666 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€418,515 2024-01-24
Overview
Total Value Won
€166,749,658,566
Contracts Won
2,781
Score 94800 · CRITICAL RISK
NIF
500165602
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.D. [P-4240]
    Gerente
    since 2024-02-12
  • J.E. [P-675a]
    Gerente
    since 2012-12-28
  • J.E. [P-675a]
    Gerente
    since 2018-02-05
  • J.C. [P-aa14]
    Gerente
    since 2026-01-30
  • D.P. [P-a798]
    Sócio
    since 2008-06-25
  • E.L. [P-4640]
    Sócio
    since 2008-06-25
  • A.L. [P-40e8]
    Gerente
    2016-12-02 → 2024-02-12
  • C.B. [P-3a7c]
    Gerente
    2024-11-22 → 2026-01-30
  • E.G. [P-a9c9]
    Gerente
    2008-11-05 → 2012-03-20
  • L.E. [P-5eeb]
    Gerente
    2024-04-19 → 2024-11-22
  • N.D. [P-c99e]
    Gerente
    2018-02-05 → 2024-04-19
  • P.L. [P-166e]
    Gerente
    2012-03-20 → 2012-12-28
  • V.R. [P-7bf5]
    Gerente
    until 2016-12-02
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned